Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ferumoxytol - AMAG Pharmaceuticals

Drug Profile

Ferumoxytol - AMAG Pharmaceuticals

Alternative Names: Feraheme; Ferrosoferric oxide; Rienso

Latest Information Update: 03 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AMAG Pharmaceuticals
  • Class Antianaemics; Contrast media; Diagnostic agents; Ferric compounds; Ferrous compounds; Heavy metals; Minerals; Vascular disorder therapies
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase II Peripheral arterial disorders

Most Recent Events

  • 26 Jul 2019 AMAG Pharmaceuticals and University of Texas Southwestern Medical Center terminate the phase I/II APART trial in Iron deficiency anaemia (in patients undergoing cardiac surgery) in USA (IV, Infusion), due to lack of infusion room (NCT02189889)
  • 01 Jun 2019 AMAG Pharmaceuticals initiates enrolment in a phase III trial for Iron deficiency anaemia (In children, In adolescent) in USA (NCT03893045)
  • 02 Apr 2019 AMAG Pharmaceuticals plans a phase III trial for Iron deficiency anaemia (In children, In adolescents, excluding patients with chronic kidney disease) in USA (IV) in May 2019 (NCT03893045)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top